Home Featured Page 204

Featured

Latest

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

Psychedelic and Mysticism: The Debate Continues

PT274 – Juan Pablo Cappello – Nue Life: Using Digital Phenotyping...

COMPASS Pathways granted fifth US patent for crystalline psilocybin

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital...

HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada

Numinus to Host Q4 and 2021 Annual Results Conference Call on...

PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent...

Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing...

Numinus to Begin Trading on the OTC Under Symbol NUMIF

1...203204205...303 Page 204 of 303

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

Psychedelic and Mysticism: The Debate Continues

PT274 – Juan Pablo Cappello – Nue Life: Using Digital Phenotyping...

COMPASS Pathways granted fifth US patent for crystalline psilocybin

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital...

HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada

Numinus to Host Q4 and 2021 Annual Results Conference Call on...

PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent...

Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing...

Numinus to Begin Trading on the OTC Under Symbol NUMIF

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY